Back to News
Market Impact: 0.28

Truist reiterates Buy on CACI stock, cites growth acceleration By Investing.com

CACIARMAPP
Analyst InsightsCorporate EarningsCompany FundamentalsInfrastructure & DefenseAnalyst Estimates
Truist reiterates Buy on CACI stock, cites growth acceleration By Investing.com

Truist reiterated a Buy on CACI International with an $800 price target, implying meaningful upside from the current $526.49 share price and above the broader analyst range of $614 to $800. The firm remains bullish on CACI’s organic growth acceleration, ARKA opportunity, and customer/product portfolio, while warning of award sluggishness and an EIT overhang affecting the rest of the government services group. CACI also reported Q3 FY2026 EPS of $7.27, beating the $6.97 consensus by 4.3%, with revenue of $2.35B in line with estimates.

Analysis

CACI is acting like the high-quality “escape hatch” in defense services: when award cadence is choppy and procurement visibility is weak, capital tends to concentrate in the name with the cleanest organic growth path and least exposure to budget noise. The market is likely underestimating how much relative multiple expansion can occur if CACI keeps printing mid-single-digit-to-high-single-digit organic growth while peers stall; in this tape, a 1-2 turn premium rerating over 1-2 quarters is more plausible than a wholesale revaluation of the group. The second-order effect is negative for lower-quality gov’t services comps and for any prime that relies more heavily on lumpy task orders or contract renewals. If management commentary across the sector confirms award sluggishness, the stock reaction can diverge sharply: CACI’s resilience can be read as both a defensive characteristic and a proxy for which business models are not yet seeing budget friction. That tends to pressure the rest of the basket first, then force estimate cuts later, creating a cleaner short opportunity in laggards than a broad sector short. The main risk to the long is that the “stand-out name” narrative is already crowded and the stock screens expensive versus intrinsic value. If there is any sign that ARKA or other growth initiatives slip, the multiple can compress quickly because the bull case is carrying a lot of future execution in current pricing. Near term, the catalyst window is the next 2-6 weeks of earnings follow-through and peer commentary; over a 6-12 month horizon, the decisive variable is whether organic growth acceleration can persist without margin giveback.